Stapled Peptides for Protein Protein Interaction Targets

Stapled peptides are one of the most exciting tools in modern drug discovery. They offer a way to target protein protein interactions that were once considered "undruggable."

What Are Stapled Peptides?

Stapled peptides are short chains of amino acids that have been chemically locked into a specific shape. The "staple" is a chemical bridge that holds the peptide in a helix form.

In nature, many peptides are floppy and lose their shape quickly. This makes them weak drug candidates because they break down fast and cannot get inside cells.

The staple fixes both of these problems. It makes the peptide stronger, more stable, and better at entering cells to do its job.

The concept of peptide stapling was first developed by Gregory Verdine at Harvard University in the early 2000s. His work opened an entirely new field of drug design.

Why Protein Protein Interactions Matter

Proteins work by touching and talking to other proteins. These contacts are called protein protein interactions, or PPIs.

PPIs control almost every process in the body. They decide when cells grow, divide, and even when they die.

When PPIs go wrong, diseases like cancer can start. For example, a protein that should tell a cell to stop growing might get blocked by another protein.

PPI Target	Disease Link	Why It Is Hard to Drug
p53/MDM2	Cancer	Large, flat binding surface
BCL-2 family	Cancer	Protein buried in membranes
Notch signaling	Cancer, fibrosis	Multiple interaction sites
Beta-catenin/TCF	Colorectal cancer	Shallow binding groove
MYC/MAX	Many cancers	Intrinsically disordered proteins

Small molecule drugs work well on targets with deep pockets or grooves. But most PPI surfaces are large and flat, making them very hard for small molecules to grab onto.

This is where stapled peptides are useful. They are big enough to cover these flat surfaces and grip them tightly.

The p53/MDM2 interaction, one of the most studied PPI targets in cancer, has a binding surface area roughly 10 times larger than the active sites typically targeted by small molecule drugs.

How Peptide Stapling Works

The stapling process involves adding special amino acids into the peptide chain. These special amino acids have side chains that can be linked together.

The most common method is hydrocarbon stapling. In this approach, two non-natural amino acids with long carbon chains are placed at specific spots in the peptide.

A chemical reaction called olefin metathesis then joins these carbon chains together. This creates a bridge, or staple, across one face of the helix.

The staple can span different distances along the helix. An "i, i+4" staple connects amino acids that are four positions apart. An "i, i+7" staple spans seven positions.

Staple Type	Positions Bridged	Helix Turns Spanned	Best For
i, i+3	3 residues	Less than 1 turn	Short peptides
i, i+4	4 residues	1 turn	Standard applications
i, i+7	7 residues	2 turns	Longer peptides
Double staple	Two bridges	Multiple turns	Maximum stability

The choice of staple type depends on the target and the peptide sequence. Getting it right takes careful design and testing.

"Stapled peptides represent a new modality that bridges the gap between small molecules and biologics. They combine the best features of both.", Dr. Loren Walensky, Dana-Farber Cancer Institute

Benefits of Stapled Peptides

Stapled peptides have several key advantages over regular peptides and small molecules. These benefits make them strong drug candidates.

Better Stability

The staple protects the peptide from enzymes that would normally break it down. This means stapled peptides last longer in the body.

Regular peptides often break down within minutes in the bloodstream. Stapled versions can survive for hours, giving them time to reach their targets.

Stronger Binding

Locking the peptide into a helix shape means it is already in the right form to bind its target. It does not waste energy changing shape before it can attach.

This pre-organized shape leads to stronger and more specific binding. The peptide fits its target like a key in a lock.

Cell Penetration

One of the notable findings about stapled peptides is that they can enter cells. Regular peptides usually cannot cross cell membranes.

The hydrocarbon staple gives the peptide a greasy, hydrophobic surface. This helps it slip through the fatty cell membrane.

Some stapled peptides can enter cells at rates comparable to small molecule drugs. This was a significant finding because most peptide drugs can only work on targets outside of cells.

Resistance to Degradation

Proteases are enzymes that break down peptides in the body. The staple blocks these enzymes from cutting the peptide chain.

This gives stapled peptides a much longer half-life. They can be given less often, which is better for patients.

Designing Stapled Peptides

Creating a good stapled peptide requires several steps. Each step needs careful thought and testing.

First, scientists identify the natural protein helix that binds the PPI target. They study the structure to find which amino acids are most important for binding.

Next, they choose where to place the staple. The staple must go on the face of the helix that does not touch the target protein.

Then they test many versions of the stapled peptide to find the best one. This involves changing the staple position, length, and the surrounding amino acids.

Computer modeling helps speed up this process. But lab testing is still needed to confirm that the designs work in real cells and animals.

For companies that need specialized peptide design expertise, working with a peptide research partner can save time and reduce risk.

When evaluating stapled peptide projects, confirm your synthesis partner has experience with olefin metathesis and can validate helical content by circular dichroism, since these steps directly determine whether the staple is working as intended.

Clinical Progress

Several stapled peptides have moved into clinical trials. The most advanced programs target cancer.

ALRN-6924 is a stapled peptide that blocks the MDM2 and MDMX proteins from shutting down p53. The p53 protein is the body's main tumor suppressor, and it is disabled in many cancers.

This drug has been tested in patients with blood cancers and solid tumors. Early results showed that it could activate p53 and shrink tumors in some patients.

Other stapled peptides in development target BCL-2 family proteins. These proteins control whether cells live or die, and blocking them can force cancer cells to self-destruct.

Drug Candidate	Target	Disease	Trial Phase
ALRN-6924	MDM2/MDMX-p53	Blood cancers, solid tumors	Phase 2
SAHB peptides	BCL-2 family	Cancer	Preclinical
Stapled BIM BH3	MCL-1	Cancer	Preclinical
Stapled Notch peptides	Notch pathway	Cancer, fibrosis	Preclinical

According to ClinicalTrials.gov, several new stapled peptide programs are expected to enter trials in the coming years. The pipeline is growing steadily.

Challenges and Limitations

Stapled peptides are not perfect. There are real challenges that scientists are still working to solve.

Manufacturing Complexity

Making stapled peptides is harder and more expensive than making regular peptides. The non-natural amino acids and stapling chemistry add cost and complexity.

Scale-up from lab to factory is tricky. Each step in the process must be carefully optimized.

Off-Target Effects

Some stapled peptides can stick to cell membranes or other proteins they should not. This can cause side effects in patients.

Careful design and testing are needed to reduce off-target binding. This takes time and money.

Oral Delivery

Most stapled peptides must be given by injection. Making them work as pills is still a big challenge.

Scientists are exploring new ways to protect stapled peptides in the gut. Progress is being made, but oral versions are still years away for most targets.

Immunogenicity

The body's immune system might see stapled peptides as foreign invaders. This could cause allergic reactions or reduce the drug's effectiveness over time.

Testing for immune reactions is a key part of clinical development. So far, most stapled peptides in trials have shown good safety profiles.

Beyond Cancer: New Applications

While cancer is the main focus today, stapled peptides have potential in many other disease areas. Researchers are exploring new uses all the time.

Infectious diseases are one promising area. Stapled peptides could block the protein interactions that viruses use to enter human cells.

Neurodegenerative diseases like Alzheimer's involve misfolded proteins that clump together. Stapled peptides might be able to prevent or break up these clumps.

Autoimmune diseases where the immune system attacks the body could also benefit. Stapled peptides might calm down overactive immune signals by disrupting specific PPIs.

For an overview of other peptide technologies changing medicine, see our guide on peptide hydrogels research.

"The versatility of stapled peptides is remarkable. Any disease driven by a protein protein interaction is a potential target, and that covers a huge portion of human disease.", Dr. Gregory Verdine, Harvard University

The Future of Stapled Peptides

The field of stapled peptides is still young and growing. Several trends will shape its future.

Better design tools powered by AI and machine learning will make it easier to create effective stapled peptides. This will cut development time and costs.

New stapling chemistries beyond hydrocarbon staples are being explored. These include lactam bridges, triazole staples, and hydrogen bond surrogates.

Combination strategies that use stapled peptides alongside other drugs are being tested. These combos could be more powerful than either drug alone.

As manufacturing methods improve, costs will come down. This will make stapled peptide drugs more accessible to patients around the world.

The first stapled peptide drug to win full approval will be a major milestone. It will prove the technology works and open the door for many more programs to follow.

Frequently Asked Questions

What makes stapled peptides different from regular peptides?

Stapled peptides have a chemical bridge that locks them into a helix shape. This makes them more stable, better at entering cells, and harder for enzymes to break down. Regular peptides are floppy, break down quickly, and usually cannot get inside cells.

Can stapled peptides replace small molecule drugs?

Stapled peptides will not replace small molecules entirely. They are best for targets that small molecules cannot reach, like large, flat protein protein interaction surfaces. Small molecules remain better for targets with deep pockets. The two approaches complement each other.

How long does it take to develop a stapled peptide drug?

From initial design to clinical trials can take five to ten years. The design and optimization phase usually takes two to three years. Preclinical testing adds another two to three years. Clinical trials can take several more years depending on the disease and trial design.

Are stapled peptides expensive to manufacture?

Yes, stapled peptides cost more to make than regular peptides or small molecules. The non-natural amino acids and stapling chemistry add to the cost. However, as the field matures and manufacturing methods improve, prices are expected to come down over time.

What diseases are stapled peptides being developed for?

Cancer is the primary focus right now, with programs targeting p53, BCL-2, and other key cancer pathways. Researchers are also exploring stapled peptides for infectious diseases, neurodegenerative diseases, autoimmune conditions, and metabolic disorders. The potential disease applications are very broad.